Edition:
United States

Profile: Chimerix Inc (CMRX.OQ)

CMRX.OQ on NASDAQ Stock Exchange Global Market

4.32USD
15 Dec 2017
Change (% chg)

$-0.07 (-1.59%)
Prev Close
$4.39
Open
$4.38
Day's High
$4.44
Day's Low
$4.32
Volume
993,281
Avg. Vol
69,919
52-wk High
$6.63
52-wk Low
$4.18

Chimerix, Inc., incorporated on April 7, 2000, is a biotechnology company. The Company is focused on discovering, developing and commercializing medicines that address unmet medical needs. Its lead compound, brincidofovir, is in development as an oral and intravenous (IV) formulation for the prevention and treatment of deoxyribonucleic acid (DNA) viruses, including smallpox, adenoviruses (AdV), and the human herpesviruses. It is also advancing the development of CMX521 for the treatment and prevention of norovirus. In addition, the Company has an active discovery program focusing on viral targets for which limited or no therapies are available.

Brincidofovir

Brincidofovir is an investigational oral nucleotide analog that has shown spectrum antiviral activity against all five families of double-stranded deoxyribonucleic acid (dsDNA) viruses that affect humans. Oral and IV formulations of brincidofovir are in development, both of which deliver the active antiviral directly to the site of viral replication. It is conducting AdVance, a retrospective, observational study of the standard-of-care for treatment of AdV in France, Germany, Italy, Spain, and the United Kingdom. The Company is collaborating with the Biomedical Advanced Research and Development Authority (BARDA) for the development of brincidofovir as a potential medical countermeasure for smallpox.

CMX157

CMX157, the Company's second clinical-stage nucleotide analog, uses the same lipid technology as brincidofovir to deliver intracellular concentrations of the potent antiviral drug, tenofovir. Tenofovir is marketed under the brand name Viread, and in multiple fixed-dose combinations, which is used for the treatment of human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infection. The Company, in collaboration with ContraVir Pharmaceuticals, is engaged in the development and commercialization of CMX157 for certain antiviral indications.

The Company competes with Gilead Sciences, Inc. and Genentech, Inc.

Company Address

Chimerix Inc

2505 Meridian Pkwy Ste 100
DURHAM   NC   27713-2288
P: +1919.8061074
F: +1919.8061146

Company Web Links